Hemmerly Nicholas H. 4

What Happened

• Nicholas H. Hemmerly, a director of Jupiter Neurosciences (JUNS), had 95,550 restricted stock units (RSUs) convert into 95,550 shares of common stock on June 2, 2025. The filing records the conversion (acquisition) with no cash paid (price N/A) and also shows a corresponding derivative disposition recorded at $0.
• This was not an open‑market buy or sale; it reflects RSU vesting/conversion rather than a purchase or cash sale.

Key Details

• Transaction date: 2025-06-02 (reported in Form 4 filed 2026-07-13 — the filing is late).
• Shares acquired on conversion: 95,550 common shares; price listed as N/A (acquisition).
• Corresponding entry: 95,550 shares disposed as a derivative at $0 in the filing (no proceeds reported).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: F1 — RSUs convert one-for-one into common stock. F2 — the RSUs vested on expiration of the IPO lock‑up period.
• Timeliness: The Form 4 was filed over a year after the transaction date, reducing prompt public transparency.

Context

• These entries reflect RSU vesting and conversion tied to the company’s IPO lock‑up expiration, not a market purchase or sale. For retail investors, such conversions increase the insider’s reported share count but do not necessarily signal a buying or selling decision.
• Because the filing is late, investors should note a gap between the transaction date and public reporting when assessing insider activity.